ENDRA Shares Rise 12% As Q2 Loss Swings To Profit; Advances Noble Africa Merger

ENDRA Life Sciences reported Q2 2026 net income of $160,000, reversing a $1.2 million loss a year earlier, while operating cash use fell to $0.9 million. The company also advanced its proposed merger with Noble Africa, expected to close in Q4 2026, with a related private placement targeting about $50 million.